AstraZeneca’s Savannah phase-II trial shows 49 per cent objective response in lung cancer…
MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targetted therapy
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Hutchmed
US FDA declines to approve two more China-tested drugs
The decisions could add pressure on Chinese stocks, especially biotech companies, at a time shares of several US-listed Chinese…